Want to see AWHL full AI Analyst Report?
Aspira Women's Health (AWHL) AI Stock Analysis
Top Page
Aspira Women's Health
(Other OTC:AWHL)
Score dragged down by severe financial weaknesses including negative equity and cash burns; partially offset by strong technical momentum and reasonable valuation for a diagnostics growth stock.
Aspira Women's Health (AWHL) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $9.79M
- Dividend Yield
- ―
- Average Volume (3M)
- 23.37K
- Price to Earnings (P/E)
- -0.1
- Beta (1Y)
- 2.94
- Revenue Growth
- -8.00%
- EPS Growth
- 47.04%
- Country
- US
- Employees
- 66
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Aspira Women's Health Business Overview & Revenue Model
Company Description
Aspira Women's Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company provides OVA1, OVERA, and OVA1plus to detect risk of ovarian malignancy i...
How the Company Makes Money
Aspira Women's Health generates revenue primarily through the sale of its diagnostic tests, such as OVA1 and Overa, to healthcare providers, hospitals, and laboratories. The company operates on a fee-for-service model, where they charge for each test...
Aspira Women's Health Earnings Call Summary
The earnings call highlighted growth in test volumes and significant achievements such as the New York State approval for OvaWatch and a major federal award for ENDOinform development. However, challenges such as severe weather impacting growth, increased expenses, and decreased cash reserves were noted. Despite these issues, the call emphasized strategic initiatives and improvements in margins, portraying a cautiously optimistic outlook.
Q3-2024 Updates
Positive Updates
Negative Updates
Company Guidance
During the third quarter of 2024, Aspira Women's Health Incorporated experienced a 4% growth in OvaSuite tests, delivering over 6,000 tests compared to approximately 5,783 in the same period in 2023. Despite severe weather, including Hurricane Helene, impacting key markets, the number of tests per sales representative rose by 21% over the first nine months of 2024 compared to 2023. The OvaSuite revenue increased by 2% to $2.3 million, with an average unit price of $376, slightly lower than the previous year's $383. Gross margins improved to 60%, and the company reported a reduction in cash used in operating activities by 12%, totaling $2.9 million for the quarter. Aspira also secured a $10 million federal award for the development of ENDOinform, enhancing its standing in the diagnostic market, while expanding its commercial reach, notably through a partnership with BioReference labs for OvaWatch distribution.
Aspira Women's Health Financial Statement Overview
Summary
Very weak profitability with deeply negative margins, negative equity signaling insolvency risk, and persistent negative cash flows despite revenue growth; overall financial distress reflected in low Income Statement (18), Balance Sheet (10), and Cash Flow (12) scores.
Income Statement
18Very NegativeBalance Sheet
10Very NegativeCash Flow
12Very NegativeAspira Women's Health Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AWHL, the sentiment is Negative. The current price of 0.21 is below the 20-day moving average (MA) of 0.22, below the 50-day MA of 0.25, and below the 200-day MA of 0.36, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 47.03 is Neutral, neither overbought nor oversold. The STOCH value of 53.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AWHL.
Aspira Women's Health Risk Analysis
Aspira Women's Health disclosed 37 risk factors in its most recent earnings report. Aspira Women's Health reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksAspira Women's Health Peers Comparison
Overall Rating
BDSX62Neutral
PRPO56Neutral- AWHL52Neutral
VNRX41Neutral
TRIB39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| BDSX | 62Neutral | $245.37M | -7.33 | -788.19% | ― | 34.46% | 43.48% |
| PRPO | 56Neutral | $32.40M | -27.85 | -8.49% | ― | 28.04% | 43.26% |
| AWHL | 52Neutral | $9.79M | -0.08 | 515.77% | ― | -8.00% | 47.04% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| VNRX | 41Neutral | $5.45M | -0.05 | 77.10% | ― | 86.32% | 21.31% |
| TRIB | 39Underperform | $4.04M | -0.14 | 48.72% | ― | -13.28% | 39.65% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AWHL | Aspira Women's Health Inc. | 0.21 | -0.27 | -56.25% | |
| TRIB | Trinity Biotech | 6.26 | -23.16 | -78.72% | |
| VNRX | VolitionRX Ltd. | 0.20 | -8.57 | -97.77% | |
| PRPO | Precipio | 18.10 | -1.87 | -9.36% | |
| BDSX | Biodesix, Inc. | 23.25 | 16.91 | 266.80% |
Aspira Women's Health Corporate Events
Aspira Women’s Health Announces CEO Leadership Transition
NeutralOn June 17, 2026, Aspira Women’s Health Inc. announced that Michael Buhle ceased serving as Chief Executive Officer, with the board appointing Chairman John Fraser as Interim CEO and Principal Executive Officer while it conducts a search for a...
Aspira Women’s Health Shareholders Approve Board and Incentive Plan
PositiveOn June 17, 2026, Aspira Women’s Health held its 2026 annual meeting of stockholders, at which holders of 62.40% of the company’s outstanding common shares were present in person or by proxy, establishing a quorum. Shareholders elected al...
Aspira Women’s Health Completes Private Equity Financing
PositiveOn June 5, 2026, Aspira Women’s Healthcare Inc. completed a private placement with accredited and institutional investors, issuing 3,300,000 shares of common stock and warrants to purchase up to 4,455,000 additional shares at a combined purchas...
Aspira Women’s Health, Cleveland Clinic Launch Diagnostics Collaboration
PositiveOn May 20, 2026, Aspira Women’s Health Inc. entered into a five-year Master Collaboration and License Agreement with Cleveland Clinic Foundation to jointly pursue biomedical research and development in women’s health diagnostics, anchored...
Aspira Women’s Health Appoints John Strahley as CFO
NeutralOn April 26, 2026, Aspira Women’s Health appointed veteran life sciences finance executive John Strahley as its Chief Financial Officer and Chief Accounting Officer, effective April 27, 2026. He joined under an executive employment agreement in...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Dec 31, 2025